marked.bio

Company

HiFiBiO Therapeutics

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

tislelizumab 2

Trials

2 of 3 trials shown

  1. A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

    Active, not recruiting Phase 1 HiFiBiO Therapeutics Started 2023Primary completion 2026-12 NCT05789069

    HFB200603tislelizumab

    BRAF V600E positive: must have received at least 2 lines of therapy

    BRAF V600ERenal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer

  2. A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

    Active, not recruiting Phase 1 HiFiBiO Therapeutics Started 2022Primary completion 2026-12 NCT05238883

    HFB200301tislelizumab

    BRAF V600E mutant: must have received at least 2 lines of therapy

    BRAF V600EGastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma